Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up

Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Artificial intelligence and machine learning can help identify complex patterns.

The trade show is expected to draw 35,000 attendees to a show floor netting more than 1 million square feet.